Key result
A low BNP value at discharge was associated with a significantly lower 1-year risk of all-cause mortality (HR 0.265) and mitigated the adverse effects of severe worsening renal function in patients with acute heart failure.
Why the study?
The impact of the degree of worsening renal function and B-type natriuretic peptide on the prognosis of patients with acute heart failure remains debatable.
Does low BNP at discharge and the degree of worsening renal function predict 1-year all-cause mortality in patients with acute heart failure?
Observational (n=440)
No
Does low BNP at discharge and the degree of worsening renal function predict 1-year all-cause mortality in patients with acute heart failure?
Effect estimate: HR 0.265 (95% CI 0.162-0.434)
Absolute Event Rate: 9.5% vs 30.9%
p-value: p=<0.001
Severe worsening renal function increases 1-year mortality in acute heart failure, but achieving a low BNP level at discharge mitigates this adverse effect.
Low discharge BNP was associated with lower mortality despite severe worsening renal function in acute HF; hypothesis-generating and should not change practice without randomized confirmation.
Background The impact of the degree of worsening renal function (WRF) and B-type natriuretic peptide (BNP) on the prognosis of patients with acute heart failure (AHF) is still debatable. The present study investigated the influence of different degrees of WRF and BNP levels at discharge on 1-year all-cause mortality in AHF. Methods Hospitalized AHF patients diagnosed with acute new-onset/worsening of chronic heart failure (HF) between January 2015 and December 2019 were included in this study. Patients were assigned into high and low BNP groups based on the median BNP level at discharge (464 pg/ml). According to serum creatinine (Scr) levels, WRF was divided into non-severe WRF (nsWRF) (Scr increased ≥0.3 mg/dl and <0.5 mg/dl) and severe WRF (sWRF) (Scr increased ≥0.5 mg/dl); non-WRF (nWRF) was defined as Scr increased of <0.3 mg/dl). Multivariable cox regression was used to evaluate the association of low BNP value and different degrees of WRF with a all-cause death, as well as testing for an interaction between the two. Results Among 440 patients in the high BNP group, there was a significant difference in WRF on mortality (nWRF vs. nsWRF vs. sWRF: 22% vs. 23.8% vs. 58.8%, P < 0.001). Yet, mortality did not significantly differ across the WRF subgroups in the low BNP group (nWRF vs. nsWRF vs. sWRF: 9.1% vs. 6.1% vs. 15.2%, P = 0.489). In multivariate Cox regression analysis, low BNP group at discharge (HR, 0.265; 95%CI, 0.162–0.434; P < 0.001) and sWRF (HR, 2.838; 95%CI, 1.756–4.589; P < 0.001) were independent predictors of 1-year mortality in AHF.There was a significant interaction between low BNP group and sWRF(HR, 0.225; 95%CI, 0.055–0.918; P < 0.05). Conclusions nsWRF does not increase the 1-year mortality in AHF patients, whereas sWRF does. A low BNP value at discharge is associated with better long-term outcomes and mitigates the adverse effects of sWRF on prognosis.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) conducted an observational in Acute heart failure (n=440). Low B-type natriuretic peptide (BNP) at discharge (<464 pg/ml) vs. High BNP at discharge (≥464 pg/ml) was evaluated on 1-year all-cause mortality (HR 0.265, 95% CI 0.162-0.434, p=<0.001). A low BNP value at discharge was associated with a significantly lower 1-year risk of all-cause mortality (HR 0.265) and mitigated the adverse effects of severe worsening renal function in patients with acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: